DIA
RCKT icon

Dana Investment Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Dana Investment Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,638
Closed -$118K – 556
2025
Q1 		$118K Buy
17,638
+30
+0.2% +$296 ﹤0.01% 537
2024
Q4 		$221K Buy
17,608
+2,627
+18% +$39.5K 0.01% 527
2024
Q3 		$277K Buy
14,981
+1,134
+8% +$23.2K 0.01% 500
2024
Q2 		$298K Buy
13,847
+586
+4% +$13.5K 0.01% 482
2024
Q1 		$357K Sell
13,261
-156
-1% -$4.43K 0.01% 470
2023
Q4 		$402K Sell
13,417
-1,992
-13% -$44K 0.02% 343
2023
Q3 		$316K Sell
15,409
-1,315
-8% -$23.9K 0.02% 357
2023
Q2 		$332K Buy
16,724
+931
+6% +$18.8K 0.02% 355
2023
Q1 		$271K Buy
15,793
+1,420
+10% +$27.8K 0.01% 363
2022
Q4 		$281K Buy
+14,373
New +$265K 0.01% 368

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Dana Investment Advisors's RCKT Position: Q2 2025 in Review

Dana Investment Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 17,638 shares — an estimated $118K sold.

Dana Investment Advisors first reported a position in RCKT in Q4 2022 and held it in 10 quarters. The position peaked at $402K in Q4 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Dana Investment Advisors reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Dana Investment Advisors sold 17,638 Rocket Pharmaceuticals shares in Q2 2025, an estimated $118K.
  • Dana Investment Advisors first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • Dana Investment Advisors's Rocket Pharmaceuticals position peaked at $402K in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Dana Investment Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.